Field Trip Health Ltd. to Commence Trading on the Toronto Stock Exchange on June 7, 2021
Field Trip Health Ltd. (CSE: FTRP; FTRP.WT; OTCQX: FTRPF) (“Field Trip”), a leader in the development and delivery of psychedelic therapies, is pleased to announce that its common shares will commence trading on the Toronto Stock Exchange (“TSX”) under the ticker symbol “FTRP” and its warrants will trade under the symbol “FTRP.WT” at the opening […]
HAVN Life Launches New Line of Natural Health Products
Seven New Formulations That Support Brain Health and Immune Function Will Be Available Online and at Select Retail Locations Starting June 3 VANCOUVER, BC / ACCESSWIRE / June 3, 2021 / HAVN Life Sciences Inc. (CNSX:HAVN.CN) (OTCPINK:HAVLF) (FSE:5NP) (the “Company” or “HAVN Life”), a Vancouver-based biotechnology company focused on brain health, is announcing the launch of its first retail […]
Mindset Selects its Lead Clinical Candidate, MSP-1014, a Next Generation Psychedelic Medicine
MSP-1014 selected based on head-to-head comparison to psilocybin and its active metabolite psilocin MSP-1014 showed greater safety and efficacy in in vitro and in vivo preclinical models Cost effective for cGMP manufacturing and IND-enabling studies Mindset Pharma Inc. (CNSX:MSET.CN) (FSE:9DF) (OTCQB:MSSTF) (“Mindset” or the “Company”), a drug discovery and development company focused on creating optimized […]
Mydecine to Participate in the H.C. Wainwright Psychedelics in Psychiatry and Beyond Conference on June 17th
Mydecine Innovations Group (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for mainstream use, today announced that Josh Bartch, CEO of Mydecine, will participate in the H.C. Wainwright Psychedelics in Psychiatry and Beyond Conference to be hosted virtually […]
